Please assess the completion status of the following clinical trial:

Trial Title: Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* has HCV GT1, GT4, or GT6 with sickle cell anemia, thalassemia, or hemophilia/von Willebrand disease~* has cirrhosis or is non-cirrhotic~* is human immunodeficiency virus (HIV) coinfected or not infected with HIV~* is a female of non childbearing potential, or is male or female and uses an acceptable method(s) of contraception~Exclusion Criteria:~* has evidence of decompensated liver disease~* is coinfected with hepatitis B~* has had a malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer~* has hepatocellular carcinoma (HCC) or is under evaluation for HCC~* has clinically-relevant drug or alcohol abuse within 12 months of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate Treatment (Type: EXPERIMENTAL): Participants will take grazoprevir 100 mg + elbasvir 50 mg once daily during the 12-week treatment period and then will be monitored for safety during a 24-week follow-up period.
- Deferred Treatment (Type: PLACEBO_COMPARATOR): Participants will take placebo tablets once daily during the 12-week treatment period and will then be monitored for safety during a 4-week follow-up period. Participants will then begin open-label treatment with grazoprevir 100 mg + elbasvir 50 mg for a 12-week treatment period and will then be monitored for safety during a 24-week follow-up period.

Based on this trial design, predict the completion outcome and termination type (if applicable).